Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Phase 3 Randomized, open-label clinical trial of tanespimycin (KO953) plus Bortezomib Compared to bortezomib alone in patients with multiple myeloma i


Collapse Overview 
Collapse sponsor award id
KOS953


Collapse Biography 

Collapse Time 
Collapse start date
2009-07-01